Dr Iain Greig

Dr Iain Greig
Dr Iain Greig
Dr Iain Greig

Reader

About
Email Address
i.greig@abdn.ac.uk
Telephone Number
+44 (0)1224 437370
Office Address

IMS 6.35 Tel 01224 437370

School/Department
School of Medicine, Medical Sciences and Nutrition

Biography

I am a medicinal chemist involved in small molecule drug discovery, with an interest in developing and commercialising new treatments for a number of different diseases. I have developed novel treatments for a wide range of disorders including: heart failure, atherosclerosis, osteoporosis, neurodegeneration, and a project which is developing a first-in-class treatment for rheumatoid arthritis, which has recently met its Phase IIa clinical trial primary endpoint. Current projects include development of allosteric modulators of the cannabinoid receptors for the treatment of depression, schizophrenia/bipolar disorder, and liver fibrosis; and novel drugs for the prevention of neurodegeneration and treatment of multiple sclerosis. 

My broader role within the Institute, as Head of Operations for the Kosterlitz Centre for Therapeutics, is to provide the expertise that allows us to identify the opportunities for target validation and drug discovery, to coordinate and fund the required multidisciplinary studies, and to manage the associated intellectual property and commercial aspects. Alongside medicinal chemistry and pharmacology, I have a background in physical organic chemistry at the University of St. Andrews and biophysics at Cornell University; I also am involved in the commercialisation process and was awarded an RSE Fellowship to provide the requisite experience, prior to founding two University of Aberdeen spin-out companies, OsteoRx (rheumatoid arthritis) and Signal Pharma (pain).  

Following on from two UK-Canada Collaboration Development awards from the Foreign and Commonwealth Office, I am a regular Visiting Professor at the University of Toronto and have a number of joint research collaborations for drug discovery projects.

I am a keen mountaineer and have climbed various peaks in the Himalayas, Andes, Rockies and Cascades; high points have been the stunning Illimani in Bolivia (6439m) and Ojos Del Salado, the world's highest volcano, in Chile (6893m).

  

Research

Research Overview

Drug Discovery, Medicinal Chemistry, Intellectual Property Management, Commercialisation

Current Research

Novel small molecule drugs for the treatment of:

  • Rheumatoid arthritis, psoriatic arthitis, psoriasis, inflammatory bowel disease
  • Multiple sclerosis
  • Schizophrenia and bipolar disorder
  • Depression
  • Non-alcoholic fatty liver disease and steatohepatitis 
  • Heart Failure
  • Osteoporosis
  • Cancer, expecially metastatic breast cancer
  • Parkinson's disease and other neurodegenerative disorders
  • Neuropathic and inflammatory pain
  • Hypertension
  • Obesity and other addictive disorders

Collaborations

The Kosterlitz Centre for Therapeutics has close links to the Toronto Centre for Collaborative Drug Research and I have a number of collaborative projects with the University of Toronto and affliated hospitals.

Funding and Grants

Motor Neurone Disease Association Development of RAR class ligands for treatment of motor neuron disease (2021–2025), £242k

Canadian Institutes for Health Research: Development and Characterization of Novel CB1 Allosteric Modulators (2020-2025), $765k

 

BBSRC PhD Studentship: Application of artificial intelligence-driven design of function-directed ligands for selective retinoic acid receptor binding (2018-2022), £93k

 

Roemex Ltd: Development of new drugs for the treatment of schizophrenia and bipolar disorder (2019–2021), $110k

 

Multiple Sclerosis Society: Identification and Characterization of Small Molecules for the Treatment of Multiple Sclerosis, (2017-2021) $838k

 

Canadian Institutes for Health Research, Proof of Principle Phase II : Development and Commercialisation of a Novel Treatment for Multiple Sclerosis, (2016-2018) $599k

 

Canadian Institutes for Health Research, Proof of Principle Phase I: Development and Validation of GPR55 Modulators for the Treatment Osteoclast-Mediated Disorders, (2016 - 2018), $155,600

 

BBSRC Follow-on Fund: Discovery that a dual-action screen (genomic/non-genomic) identifies retinoic acid receptor ligands of highest neurotrophic potency, (2017 - 2019), £249,710

 

Canadian Institutes for Health Research, Proof of Principle Phase II: Development and Commercialisation of Allosteric Modulators for the Treatment of Pain, (2015 - 2018), $489,920

Medical Research Council, Confidence in Concept: The Aberdeen Translational Accelerator Fund: bridging biomedical innovation and translational impact, (2015 – 2016), £200,000

Foreign and Commonwealth Office, UK-Canada Collaboration Development Awards, (2014 and 2015)

Signal Pharma Ltd: Development of a novel treatment for heart failure; (2013-2017), £151,274

Canadian Institutes for Health Research, Proof of Principle Phase I: Development and Testing of Small Molecule Allosteric Modulators for the Treatment of Pain, (2013–2014), $157,999

MSD SULSA Postdoctoral Fellowship: Development and Application of new fluorination techniques in the synthesis of therapeutics and diagnostics. (2013 – 2015)

MSD SULSA Postdoctoral Fellowship: Identification of compounds to interfere with chitin synthesis.  (2013 – 2014)

MSD SULSA, PhD Studentship: A Novel Hypothalamic Receptor in Obesity and Metabolic Health, (2012-2015)

Tenovus, PhD Studentship: A Novel glutamate receptor. (2012 – 2015)

BBSRC: Development and Testing of Peripherally-restricted small molecule allosteric Inhibitors of the Cannabinoid CB1 Receptor, (2011 – 2012)

Development Trust: A novel therapy for diastolic heart failure, (2011 - 2013)

SULSA: Fragment-based Screening for Development of Inhibitors targeting a Vulnerable Epitope on HIV-1 Envelope Glycoprotein, (2012-2013)

SULSA Chemistry Catalyst Fund:  Development of stable tumour-targeting peptide vectors;  (2011)

SULSA Chemistry Catalyst Fund: Development of novel DDAH inhibitors for the treatment of neurodegenerative diseases; (2011)

SULSA Chemistry Catalyst Fund:  Peripherally-restricted CB1 Allosteric Inhibitors for the Treatment of Type-2 Diabetes; (2011)

Development Trust: Commercial Validation of Kosterlitz Centre for Therapeutics Projects; Greig IR, Ross RA, Bewick G; Zanda M, Gow N (2011 - 2012)

Knowledge Transfer Grant: Screening of a Natural Product Library for Novel Chemotherapeutic Agents; (2010)

Parkinson's Disease Society:   Assessment of a novel lead structure for the neuroprotective treatment of Parkinson's disease; (2010 - 2011)

Knowledge Transfer Grant: A Novel Retinoid Receptor with Therapeutic Potential;  (2010) 

BBSRC: Development and Testing of Small Molecule Allosteric Enhancers of the Cannabinoid CB1 Receptor; (2009 – 2010)

Knowledge Transfer Grant: Novel HTS platform for drug discovery in neurodegenerative disease; (2009)

NESTech (Scottish Universities Challenge Fund): Targeting novel receptors involved in metastatic breast cancer; (2009 - 2010)

SULSA: Discovery of lead small molecules targeting the allosteric binding site on the cannabinoid CB1 receptor; (2009)

Knowledge Transfer Grant: Allosteric modulators of the cannabinoid receptors for pain relief;  (2008)

NESTech (Scottish Universities Challenge Fund): A Novel treatment for obesity; (2008 - 2009)

Modern Biosciences: Novel Anti-inflammatory agents; (2007 – 2010)

Knowledge Transfer Grant: A Neuroprotective therapy for Parkinson's disease; (2007)

Knowledge Transfer Grant: Commercialisation of Cannabinoid-based projects; (2006 – 2008)

NESTech (Scottish Universities Challenge Fund): Novel Bone Resorption Inhibitors;  (2006 – 2008)

Arthritis Research Campaign: Small molecule inhibitors of TNF signalling as novel anti-rheumatic agents; (2005 – 2007)

Scottish Enterprise, Proof of Concept Follow on: Novel Bone Resorption Inhibitors; (2005 – 2006)

Royal Society of Edinburgh Enterprise Fellowship in Biotechnology: Novel therapeutic agents for bone disease; (2003 – 2004)

Scottish Enterprise, Proof of concept: Novel Bone Resorption Inhibitors: (2002 - 2004)

Teaching

Teaching Responsibilities

I am the coordinator for the undergraduate Biobusiness Programme

I am the course coordinator for

  • BT2501 (Introduction to Biobusiness and Bioentrepreneurship
  • SM3004 (Frontiers of Molecular Medicine and Therapeutics)
  • BT3502 (Biobusiness)
  • BT4506 (Advanced Biobusiness)
  • BT5016 (Introduction to Commercialisation and Biobusiness

I contribute to the teaching and delivery of

  • MC3504 (Molecular Microbiology)
  • BT5013 (Small Molecule Drug Discovery)
  • BT5015 (Introduction to Commercialisation and Biobusiness)
  • BT5508 (Advanced Biobusiness and the Commercialisation of Bioscience)

 

Publications

Page 1 of 2 Results 1 to 50 of 57

  • The atypical 'hippocampal' glutamate receptor coupled to phospholipase D that controls stretch-sensitivity in primary mechanosensory nerve endings is homomeric purely metabotropic GluK2

    Thompson, K. J., Watson, S., Zanato, C., Dall'Angelo, S., De Nooij, J. C., Pace-Bonello, B., Shenton, F. C., Sanger, H. E., Heinz, B. A., Broad, L. M., Grosjean, N., McQuillian, J. R., Dubini, M., Pyner, S., Greig, I., Zanda, M., Bleakman, D., Banks, R. W., Bewick, G. S.
    Experimental Physiology, vol. 109, no. 1, pp. 81-99
    Contributions to Journals: Articles
  • Small-molecule Targeting AMPA-mediated Excitotoxicity Has Therapeutic Effects in Mouse Models for Multiple Sclerosis

    Zhai, D., Yan, S., Samsom, J., Wang, L., Su, P., Jiang, A., Zhang, H., Jia, Z., Wallach, I., Heifets, A., Zanato, C., Tseng, C., Wong, A. H. C., Greig, I., Liu, F.
    Science Advances, vol. 9, no. 49
    Contributions to Journals: Articles
  • In vitro characterisation of 6-methyl-3-(2-nitro-1-(thiophen- 2-yl)ethyl)-2-phenyl-1Hindole (ZCZ011) at the type 1 cannabinoid receptor: allosteric agonist or allosteric modulator?

    Green, H. M., Finlay, D. B., Ross, R. A., Greig, I., Duffull, S. B., Glass, M.
    ACS pharmacology & translational science, vol. 5, no. 12, pp. 1279–1291
    Contributions to Journals: Articles
  • Motor-like Tics are Mediated by CB2 Cannabinoid Receptor-dependent and Independent Mechanisms Associated with Age and Sex

    Gorberg, V., Borisov, V., Greig, I., Pertwee, R., McCaffery, P., Anavi-Goffer, S.
    Molecular Neurobiology, vol. 59, pp. 5070-5083
    Contributions to Journals: Articles
  • Antidepressant Activity of Pharmacological and Genetic Deactivation of the Small-Conductance Calcium-Activated Potassium Channel Subtype-3

    Nashed, M., Waye, S., Hasan, S. N., Nguyen, D., Wiseman, M., Zhang, J., Lau, H., Dinesh, O. C., Raymond, R., Greig, I., Rodriguez Bambico, F., Nobrega, J.
    Psychopharmacology, vol. 239, no. 1, pp. 253-266
    Contributions to Journals: Articles
  • A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models

    Mielnik, C. A., Sugamori, K. S., Finlay, D. B., Thorpe, H. H. A., Schapira, M., Sivananthan, N., Li, C. K., lam, V. M., Harrington, S., Abdelrahman, M. H., Trembleau, L. A., Burnham, W. M., Khokhar, J. Y., Salahpour, A., Ramsey, A. J., Glass, M., Greig, I. R., Ross, R. A.
    Neuropsychopharmacology, vol. 46, no. 2, pp. 413-422
    Contributions to Journals: Articles
  • Evidence that cannabinoid CB1 receptors regulate intraocular pressure via two opposing mechanisms

    Miller, S., Daily, L., Ploss, M., Greig, I., Ross, R., Rayana, N. P., Dai, J., Sugali, C. K., Mao, W., Straiker, A.
    Experimental Eye Research, vol. 200, 108241
    Contributions to Journals: Articles
  • Genomic and non-genomic pathways are both crucial for peak induction of neurite outgrowth by retinoids

    Khatib, T., Marini, P., Nunna, S., Chisholm, D. R., Whiting, A., Redfern, C., Greig, I. R., McCaffery, P.
    Cell Communication and Signaling, vol. 17, 40
    Contributions to Journals: Articles
  • Synthetic Retinoids for Use in RAR Mediated Conditions

    Whiting, A., Chisholm, D., Valentine, R., Greig, I. R., McCaffery, P. J. A., Alkhatib, T.
    Patents: Patents
  • The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB1 Receptor Positive Allosteric Modulators (PAMs)

    Tseng, C., Baillie, G., Donvito, G., Mustafa, M. A., Juola, S. E., Zanato, C., Massarenti, C., Dall'angelo, S., Harrison, W. T. A., Lichtman, A. H., Ross, R. A., Zanda, M., Greig, I. R.
    Journal of Medicinal Chemistry, vol. 62, no. 10, pp. 5049-5062
    Contributions to Journals: Articles
  • Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia

    Wat, J. M., Hawrylyshyn, K., Baczyk, D., Greig, I. R., Kingdom, J. C.
    Biology of Reproduction, vol. 99, no. 5, pp. 1082-1090
    Contributions to Journals: Articles
  • Small Molecule Inhibitors of Metabolic Enzymes Repurposed as a New Class of Anthelmintics

    Tyagi, R., Maddirala, A. R., Elfawal, M., Fischer, C., Bulman, C. A., Rosa, B. A., Gao, X., Chugani, R., Zhou, M., Helander, J., Brindley, P. J., Tseng, C., Greig, I. R., Sakanari, J., Wildman, S. A., Aroian, R., Janetka, J. W., Mitreva, M.
    ACS Infectious Diseases, vol. 4, no. 7, pp. 1130–1145
    Contributions to Journals: Articles
  • Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons

    Mitjavila, J., Yin, D., Kulkarni, P. M., Zanato, C., Thakur, G. A., Ross, R., Greig, I., Mackie, K., Straiker, A.
    Pharmacological Research, vol. 129, pp. 475-481
    Contributions to Journals: Articles
  • Synthetic retinoids for use in RAR mediated conditions

    Greig, I. R., McCaffery, P. J. A., Whiting, A., Valentine, R., Chisholm, D., Khatib, T.
    Patents: Patents
  • Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy

    Tseng, C., Noordali, H., Sani, M., Madhani, M., Grant, D. M., Frenneaux, M., Zanda, M., Greig, I. R.
    Journal of Medicinal Chemistry, vol. 60, no. 7, pp. 2780-2789
    Contributions to Journals: Articles
  • Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators

    Greig, I. R., Baillie, G. L., Abdelrahman, M. H., Trembleau, L., Ross, R. A.
    Bioorganic & Medicinal Chemistry Letters, vol. 26, no. 18, pp. 4403-4407
    Contributions to Journals: Articles
  • N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

    Smith, S., Patel, L., Greig, I. R.
    Patents: Patents
  • Asymmetric Synthesis and Absolute Configuration of (+)- and (–)-Perhexiline

    Tseng, C., Greig, I. R., Harrison, W. T. A., Zanda, M.
    Synthesis, vol. 48, no. 01, pp. 73-78
    Contributions to Journals: Articles
  • A Cannabinoid CB 1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects

    Ignatowska-Jankowska, B. M., Baillie, G. L., Kinsey, S., Crowe, M., Ghosh, S., Owens, R. A., Damaj, I. M., Poklis, J., Wiley, J. L., Zanda, M., Zanato, C., Greig, I. R., Lichtman, A. H., Ross, R. A.
    Neuropsychopharmacology, vol. 40, pp. 2948-2959
    Contributions to Journals: Articles
  • HPLC-MS-MS Determination of ZCZ-011, A Novel Pharmacological Tool for Investigation of the Cannabinoid Receptor in Mouse Brain Using Clean Screen FASt™ Column Extraction

    Poklis, J. L., Clay, D. J., Ignatowska-Jankowska, B. M., Zanato, C., Ross, R. A., Greig, I. R., Abdullah, R. A., Mustafa, M. A., Lichtman, A. H., Poklis, A.
    Journal of analytical toxicology, vol. 39, no. 5, pp. 353-359
    Contributions to Journals: Articles
  • Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism

    Menzfeld, C., John, M., van Rossum, D., Regen, T., Scheffel, J., Janova, H., Götz, A., Ribes, S., Nau, R., Borisch, A., Boutin, P., Neumann, K., Bremes, V., Wienands, J., Reichardt, H. M., Lühder, F., Tischner, D., Waetzig, V., Herdegen, T., Teismann, P., Greig, I., Müller, M., Pukrop, T., Mildner, A., Kettenmann, H., Brück, W., Prinz, M., Rotshenker, S., Weber, M. S., Hanisch, U.
    Glia, vol. 63, no. 6, pp. 1083-1099
    Contributions to Journals: Articles
  • Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459

    Goonawardena, A. V., Plano, A., Robinson, L., Ross, R., Greig, I., Pertwee, R. G., Hampson, R. E., Platt, B., Riedel, G.
    Behavioural Pharmacology, vol. 26, no. 3, pp. 289-303
    Contributions to Journals: Articles
  • Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice

    Coste, E., Greig, I. R., Mollat, P., Rose, L., Gray, M., Ralston, S. H., van 't Hof, R. J.
    Annals of the Rheumatic Diseases, vol. 74, no. 1, pp. 220-226
    Contributions to Journals: Articles
  • Fluoro-perhexiline compounds and their therapeutic use

    Greig, I. R., Tseng, C., Zanda, M.
    Patents: Patents
  • In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569

    Gamage, T. F., Ignatowska-Jankowska, B. M., Wiley, J. L., Abdelrahman, M., Trembleau, L., Greig, I. R., Thakur, G. A., Tichkule, R., Poklis, J., Ross, R. A., Pertwee, R. G., Lichtman, A. H.
    Behavioural Pharmacology, vol. 25, no. 2, pp. 182-185
    Contributions to Journals: Articles
  • N-(4-Hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-Hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzene sulfonamides and their therapeutic use

    Patel, L., Smith, S., Greig, I. R., Williams, S.
    Patents: Patents
  • Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use

    Greig, I. R., Sheridan, R. M., Fisher, R., Tozer, M. J., Clase, J. A., Smith, A., Tufnell, A. R., van 't Hof, R. J.
    Patents: Patents
  • Synthesis and structure–activity relationship studies of novel tubulysin U analogues – effect on cytotoxicity of structural variations in the tubuvaline fragment

    Shankar, S. P., Jagodzinska, M., Malpezzi, L., Lazzari, P., Manca, I., Greig, I. R., Sani, M., Zanda, M.
    Organic & Biomolecular Chemistry, vol. 11, no. 14, pp. 2273-2287
    Contributions to Journals: Articles
  • 18f-labelled barbiturate compounds for use as positron emission imaging agents

    Greig, I. R., Zanda, M., Platt, B., Calamai, E.
    Patents: Patents
  • Development of triarylsulfonamides as novel anti-inflammatory agents

    Greig, I. R., Emmanuel, C., Ralston, S., van 't Hof, R.
    Bioorganic & Medicinal Chemistry Letters, vol. 23, no. 3, pp. 816-820
    Contributions to Journals: Articles
  • Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids

    Anavi-Goffer, S., Baillie, G., Irving, A., Gertsch, J., Greig, I. R., Pertwee, R. G., Ross, R. A.
    The Journal of Biological Chemistry, vol. 287, no. 1, pp. 91-104
    Contributions to Journals: Articles
  • N-(ARYLALKYL)-1H-INDOLE-2-SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS

    Greig, I. R., Ross, R. A., Trembleau, L. A. C., Pertwee, R. G., Abdelrahman, M. H.
    Patents: Patents
  • The biphenyl-carboxylate derivative ABD328 is a novel orally active antiresorptive agent

    Idris, A. I., Coste, E., Greig, I. R., Ralston, S. H., van't Hof, R. J.
    Calcified Tissue International, vol. 87, no. 6, pp. 525-532
    Contributions to Journals: Articles
  • Discovery of biphenylketones as dual modulators of inflammation and bone loss

    Greig, I. R., Coste, E., Ralston, S. H., van't Hof, R. J.
    Bioorganic & Medicinal Chemistry Letters, vol. 20, no. 18, pp. 5548-5551
    Contributions to Journals: Articles
  • Aryl-phenyl-sulfonamide-cycloalkyl compounds and their use

    Greig, I. R., Clase, J. A., Fisher, R., Sheridan, R. M., Smith, A., Tozer, M. J., Tufnell, A. R.
    Patents: Patents
  • Aryl-phenyl-sulfonamide-phenylene compounds and their use

    Greig, I. R., Clase, J. A., Fisher, R., Sheridan, R. M., Smith, A., Tozer, M. J., Tufnell, A. R., van 't Hof, R. J.
    Patents: Patents
  • 1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists

    Greig, I. R., Ross, R. A.
    Patents: Patents
  • Neuroprotective 3-phenylacrylonitrile (3-PAN) derivatives

    Greig, I. R., Teismann, P., Hanisch, U., Bruck, W.
    Patents: Patents
  • Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation

    Idris, A. I., Greig, I. R., Bassonga-Landao, E., Ralston, S. H., van't Hof, R. J.
    Endocrinology, vol. 150, no. 1, pp. 5-13
    Contributions to Journals: Articles
  • Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions

    Greig, I. R., Ralston, S., Idris, A. I., Van't Hof, R. J.
    Patents: Patents
  • Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions

    Greig, I. R., Ralston, S., Van T Hof, R. J., Mohamed, A. I. I.
    Patents: Patents
  • 2',4'-Dichloro-biphenyl-4-yl-hydroxyketones and related compounds and their use as therapeutic agents

    Greig, I. R., Van T Hof, R. J., Ralston, S.
    Patents: Patents
  • 1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents

    Greig, I. R., Ross, R. A., Pertwee, R. G.
    Patents: Patents
  • ABD56 causes osteoclast apoptosis by inhibiting the NFkappaB and ERK pathways

    Idris, A. I., Mrak, E., Greig, I. R., van't Hof, R. J., Ralston, S. H.
    Biochemical and Biophysical Research Communications, vol. 371, no. 1, pp. 94-98
    Contributions to Journals: Articles
  • Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro

    Idris, A. I., Rojas-Navea, J., Greig, I. R., van't Hof, R. J., Ralston, S.
    Calcified Tissue International, vol. 82, no. 3, pp. 191-201
    Contributions to Journals: Articles
  • Biphenyl-4-yl-sulfonic acid arylamines and their use as therapeutic agents

    Greig, I. R., van't Hof, R. J., Ralston, S.
    Patents: Patents
  • Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption

    Greig, I. R., Idris, A. I., Ralston, S. H., van't Hof, R. J.
    Journal of Medicinal Chemistry, vol. 49, no. 25, pp. 7487-7492
    Contributions to Journals: Articles
  • Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors

    Idris, A. I., van't Hof, R. J., Greig, I. R., Ridge, S., Baker, D., Ross, R. A., Ralston, S. H.
    Nature Medicine, vol. 11, no. 7, pp. 774-779
    Contributions to Journals: Articles
  • Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors

    van't Hof, R. J., Idris, A. I., Ridge, S., Dunford, J. E., Greig, I. R., Ralston, S.
    Journal of Bone and Mineral Research, vol. 19, no. 10, pp. 1651-1660
    Contributions to Journals: Articles
  • Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders

    Greig, I. R., Mohamed, A. I. I., Ralston, S., Ross, R. A., Van T Hof, R. J.
    Patents: Patents
Show 10 | 25 | 50 | 100 results per page

Refine

Contributions to Journals

Patents